Looking to expand beyond diabetes, Novo Nordisk enlists Evotec in CKD pact worth up to $179M per program
Most of Novo Nordisk’s kidney work has come from diabetes, but eyeing an R&D expansion, the Danish giant is putting money down on a pact …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
